---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-092722"
form_type: "8-K"
ticker: "BDSX"
cik: "0001439725"
company_name: "BIODESIX INC"
filed_at: "2024-08-07T23:59:59+00:00"
generated_at: "2026-05-31T11:41:51.471362+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Biodesix Q2 revenue up 51% YoY to $17.9M; raises FY2024 guidance to $70-72M

## Summary
- Q2 2024 revenue $17.9M, up 51% YoY; Lung Diagnostic $16.5M (+44%), Biopharma Services $1.4M (+228%).
- Gross margin 78.4% vs 72.7% Q2 2023; net loss improved 19% to $10.8M; Adjusted EBITDA loss improved 38% to $5.6M.
- Raises full-year 2024 revenue guidance to $70-72M from prior $65-68M.
- Lung diagnostic test volume 13,900, up 42% YoY and 17% sequentially.
- Cash $42.2M at June 30, 2024, including $55M from April stock offering.

## SEC filing metadata
- accession: 0000950170-24-092722
- form_type: 8-K
- ticker: BDSX
- cik: 0001439725
- company_name: BIODESIX INC
- filed_at: 2024-08-07T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1439725/000095017024092722/0000950170-24-092722-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1439725/000095017024092722/bdsx-20240807.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-092722
- JSON: https://secwatch.observer/filing/0000950170-24-092722.json
- Plain text: https://secwatch.observer/filing/0000950170-24-092722.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.